ERNA vs. ANVS, RANI, FGEN, PLUR, PEPG, AADI, ACRV, SNTI, EGRX, and PYRGF
Should you be buying Ernexa Therapeutics stock or one of its competitors? The main competitors of Ernexa Therapeutics include Annovis Bio (ANVS), Rani Therapeutics (RANI), FibroGen (FGEN), Pluri (PLUR), PepGen (PEPG), Aadi Bioscience (AADI), Acrivon Therapeutics (ACRV), Senti Biosciences (SNTI), Eagle Pharmaceuticals (EGRX), and PyroGenesis Canada (PYRGF). These companies are all part of the "pharmaceutical products" industry.
Ernexa Therapeutics vs. Its Competitors
Annovis Bio (NYSE:ANVS) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.
Annovis Bio presently has a consensus price target of $17.33, indicating a potential upside of 656.58%. Given Annovis Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Annovis Bio is more favorable than Ernexa Therapeutics.
Annovis Bio has higher earnings, but lower revenue than Ernexa Therapeutics. Annovis Bio is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 20.8% of Annovis Bio shares are held by insiders. Comparatively, 1.5% of Ernexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Annovis Bio has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%. Ernexa Therapeutics' return on equity of 0.00% beat Annovis Bio's return on equity.
Annovis Bio has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 5.65, indicating that its stock price is 465% more volatile than the S&P 500.
In the previous week, Annovis Bio had 10 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 12 mentions for Annovis Bio and 2 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.50 beat Annovis Bio's score of -0.42 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.
Summary
Annovis Bio beats Ernexa Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Ernexa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ernexa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ERNA) was last updated on 9/5/2025 by MarketBeat.com Staff
Free ERNA Stock Alerts